How Mounjaro works in the body — and why it's different from other weight-loss medicines

The common misconception: Mounjaro is just a stronger version of Wegovy

This is probably the most persistent misunderstanding about tirzepatide, and it's worth clearing up directly. Mounjaro and Wegovy are not the same kind of medicine at different strengths. Wegovy (semaglutide) is a GLP-1 receptor agonist, it mimics one gut hormone. Mounjaro mimics two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). These are distinct hormones with distinct roles, and activating both together produces a different physiological response from either alone.

GLP-1 is released from the gut after eating and signals to the brain that you are full. It also slows gastric emptying and encourages the pancreas to release insulin in response to food. GIP, which most people have never heard of, amplifies the insulin signal further and also acts on fat tissue and the brain in ways that are still being studied. The combination appears to produce stronger appetite suppression and greater average weight loss than GLP-1 activation alone, the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, found tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes.

So the distinction matters practically. If you've been on Wegovy and found the appetite suppression partial, the different mechanism of tirzepatide is a clinically relevant reason to explore switching, via a prescriber, not by guesswork. You can read more about the two pathways side by side on our page covering how tirzepatide works in the body.

The brain, the gut, and the stomach: where the signals actually land

When you inject Mounjaro, the molecule circulates and binds to GIP and GLP-1 receptors in several locations at once. The hypothalamus (the part of the brain most involved in hunger and energy balance) receives signals through both pathways telling it to reduce appetite and increase the sense of satiety. This is not a vague, gentle nudge; for many people on the higher doses, it produces a marked reduction in how often food enters their thoughts and how much they want to eat at a sitting.

At the stomach, tirzepatide slows gastric emptying: food moves from the stomach into the small intestine more slowly than usual. That means you feel fuller for longer after a meal. It also blunts the sharp post-meal glucose spike that can trigger renewed hunger relatively quickly after eating. For people with type 2 diabetes this has obvious benefits, which is why tirzepatide also holds a UK licence for that condition, and our page on tirzepatide in the EU sets out how the regulatory picture compares across borders for those who want that context.

There's emerging research into what tirzepatide does specifically in the brain, which we've covered separately for those who want the detail on how Mounjaro works in the brain. The short version: the appetite-reducing effect is partly central (brain) and partly peripheral (gut and stomach), and the two signals reinforce each other.

The NHS tirzepatide medicines page offers a clear patient-level explanation of how the drug works and what to expect during treatment.

Why the dose starts low and builds, and what to expect at each stage

Mounjaro is available in six strengths: 2.5, 5, 7.5, 10, 12.5, and 15mg. Treatment always begins at 2.5mg, typically for the first four weeks. This is a tolerability phase; the 2.5mg dose exists to let your digestive system adjust before the appetite effects become pronounced. Many people notice relatively little change in hunger at this stage. That's expected. The nausea and other gastrointestinal effects that some people experience are most common when starting or after a dose increase, and beginning low significantly reduces their severity.

From 5mg upwards, the dual-pathway mechanism becomes more noticeable for most people. Appetite decreases, meals feel satisfying at smaller portions, and the mental preoccupation with food often lessens. The prescriber increases the dose in roughly four-week steps, but the pace is guided by how you're tolerating the current level, not by a fixed calendar. If you ordered on a Monday in December before the Christmas break, your next dose review timing works the same way: the prescriber looks at your response, not the date.

The SURMOUNT-1 trial (2,539 adults with obesity and no diabetes, 72 weeks) reported average body-weight reductions of around 20–21% at the 15mg dose, results that led to NICE recommending tirzepatide for NHS use in eligible adults in December 2024. For more on the weight-loss evidence specifically, our page explaining how Mounjaro works for weight loss covers the trial data in more depth, including the mechanisms behind those outcomes. If you'd like a broader look at the science behind the medicine first, our page on how Mounjaro works is a good starting point before diving into the trial figures. These are prescription-only medicines, so a named prescriber assesses your suitability; results vary between individuals.

Side effects, practical expectations, and when to get medical help

The most common side effects of tirzepatide are gastrointestinal: nausea, vomiting, diarrhoea, constipation, indigestion, and burping. These are direct consequences of the gastric-emptying slowdown and, for most people, are most noticeable after starting or after a dose increase. They tend to settle within days to a couple of weeks. Eating smaller meals, avoiding fatty or rich foods, and staying well hydrated helps.

A small number of people experience fatigue, headache, or dizziness, particularly early in treatment. Injection-site reactions are possible but usually mild.

More serious effects are rare but require prompt attention. Severe, persistent abdominal pain that radiates to the back (with or without vomiting) may indicate pancreatitis, which the MHRA highlighted as a known infrequent but serious effect of GLP-1 medicines in a Drug Safety Update issued in January 2026. Seek urgent medical help if this occurs. Symptoms of gallbladder problems, serious allergic reactions, or signs of significant dehydration from severe vomiting or diarrhoea also warrant medical attention promptly.

You can report suspected side effects directly at the MHRA Yellow Card scheme. If you're weighing up the full picture of effects before deciding whether to go ahead, our Mounjaro overview page covers the broader context, and our prescribers are available through aftercare seven days a week once you've started treatment.

If you'd like to explore whether tirzepatide could be right for you, start your free consultation and a GPhC-registered prescriber will review your information the same day.